Hostname: page-component-cd9895bd7-hc48f Total loading time: 0 Render date: 2024-12-25T13:19:30.257Z Has data issue: false hasContentIssue false
  • English
  • Français

Autoanticuerpos antinucleares en relación con el trastorno afectivo bipolar y la terapia de litio

Published online by Cambridge University Press:  12 May 2020

B. Spivak ,
M. Radwan ,
P. Bartur ,
R. Mester  and
A. Weizman
B. Spivak
Affiliation:
Unidad de Investigación, Hospital Psiquiátrico de Ness Ziona, Ness Ziona
M. Radwan
Affiliation:
Hospital Psiquiátrico Geha, Centro Médico Beilinson, Facultad Sackler de Medicina, Universidad de Tel Aviv, Tel Aviv
P. Bartur
Affiliation:
Laboratorio de Inmunología Clínica, Centro de Laboratorios Zamenhoff, Tel Aviv
R. Mester
Affiliation:
Unidad de Investigación, Hospital Psiquiátrico de Ness Ziona, Ness Ziona
A. Weizman
Affiliation:
Laboratorio de Psiquiatría Biológica, Centro de Investigación Médica Felsenstein, Centro Médico Beilinson, y Unidad de Investigación, Hospital Psiquiátrico de Geha, Facultad Sackler de Medicina, Universidad de Tel Aviv, Tel Aviv, Israel
Get access

Resumen

Investigamos la presencia de anticuerpos antinucleares (ANA) en 63 pacientes bipolares sin medicación y tratados con litio en comparación con 37 controles sanos. Se detectó una mayor frecuencia de ANA positivos en pacientes bipolares en comparación con los controles (19% frente a 5%, respectivamente, P < 0,05). Este resultado no estaba relacionado con el tratamiento de litio. No se detectaron anticuerpos anti-DNA nativo o anticuerpos reactivos a antihistona entre los sujetos positivos a ANA.

Keywords

trastorno afectivo bipolarlitioanticuerpos antinucleares (ANA)autoinmunidad
Type
Comunicación breve
Information
European Psychiatry (Ed. Española) , Volume 3 , Issue 3 , June 1996 , pp. 203 - 206
Copyright
Copyright © European Psychiatric Association 1996

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Bibliografia

Aranth, JJohnson, RKataria, PVan de Water, SKamal, MMiller, M. Immune dysfunction in psychiatric patients. Psych J Univ Ottawa 1989; 14: 542–6.Google Scholar
Dorian, BGarfinkel, P. Stress, immunity and illness - a review. Psychol Med 1987; 17: 393–407.CrossRefGoogle ScholarPubMed
Epstein, AGreenberg, MHalbert, SKramer, LBarland, P. The clinical application of an ELISA technique for the detection of antihistone antibodies. J Rheumatol 1983; 13: 304–7Google Scholar
Hart, DAZhao, PLen, ZSet al. Lithium treatment o f MRL-Ipr mice alters disease progression in this murene model of systemic lupus erythematosus. Lithium 1991; 4: 61–8.Google Scholar
Irwin, MCaldwell, CSmith, TLBrown S, , Schuckit MA, Gillin JC. Major depressive disorder, alcoholism, and reduced natural killer cell sytotoxicity. Arch Gen Psychiatry 1990; 47: 713–18.CrossRefGoogle Scholar
Jansen, EMPeng, JSBeutner, EHKumar, VChorzeski, T. Comparison of commercial kits for the detection of anti n-DNA antibodies using Crithidiae Iuciliae. Am J Clin Pathol 1987; 87: 461–9.CrossRefGoogle Scholar
Johnstone, ECWhaley, K. Antinucelar antibodies in psychiatric illness: their relationship to diagnosis and drug treatment. Br Med J 1975; i: 724–5.CrossRefGoogle Scholar
Kronfel, ZSilva, JGreden, JDembinski, SGardner, RCarrol, B. Impaired lymphocyte function in depressive illness. Life Sci 1983; 33: 241–7.CrossRefGoogle Scholar
Lazarus, LMKitron, N. Depression of DNA-polimerase activity by lithium. Lancet 1974; ii: 225–6.CrossRefGoogle Scholar
Presley, APKahn, AWilliamson, N. Antinuclear antibodies in patients on lithium carbonate. Br Med J 1976; ii: 280–1.CrossRefGoogle Scholar
Prost, ACAbuaf, NRouquette-Gally, MHomberg, JCCombrisson, A. Comparing HEp-2 cell line with rat liver in routine screening test for antinuclear and antinucleolar auto-antibodies in au toimmune diseases. Ann Biol Clin 1987; 45: 610–17.Google Scholar
Schleifer, SJKeller, SEMeyerson, ATRaskin, MJDavis, KLStein, M. Lymphocyte function in major depressive disorder.Arch Gen Psychiatry 1984; 41: 484–6.CrossRefGoogle Scholar
Solomon, GFAllansmith, MMcClellan, BAmkraut, A. Immunoglobulins in psychiatric patients. Arch Gen Psychiatry 1969; 20: 212–1.CrossRefGoogle ScholarPubMed
Spitzer, RLEdincott, J. Schedule for ajfective disorders and schizophrenia - lifetime version 3rd ed. New York, New York Psychiatric Institute. 1979.Google Scholar
Stein, MMiller, AHTrestman, RL, Depression the immune System and health and illness. Arch Gen Psychiatry 1991; 48: 171–7.CrossRefGoogle ScholarPubMed
Tan, EM. Antinuclear antibodies in diagnosis and management. Hospital Practice 1983; 18: 79–84.CrossRefGoogle ScholarPubMed
Villemain, FMagnin, MFeuillet-Fieux, MNZarifian, ELoo, HBach, JF. Antihistone antibodies in schizophrenia and affective disorders. Psychiatry Res 1988; 24: 53–60.CrossRefGoogle Scholar
Von Brauchitsch, H. Antinuclear factor in psychiatric disorders. Am J Psychiatry 1972; 128: 1552–4.CrossRefGoogle ScholarPubMed
Whalley, LJRoberts, DFWentzel, JWatson, KC. Antinuclear antibodies and histocompatibility antigens in patients on long-term lithium therapy. J Affective Disord 1981; 3: 123–30.CrossRefGoogle ScholarPubMed